BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS. Libra Therapeutics Inc. emerged from stealth Wednesday...
BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

RA Capital to fund Novavax Novavax Inc. (NASDAQ:NVAX) said Monday it will raise $200 million through a private placement of 4.4 million shares at $45.57, its closing price on Friday, to RA Capital Management. The...
BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

Lumos finds public pat h Rare disease company Lumos Pharma Inc. plans to go public via a reverse merger with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’...
BioCentury | Jun 28, 2019
Company News

Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more

...She was chair of Mintz’s FDA practice. BioCentury Staff Adaptimmune Adaptimmune Ltd. Ambys Medicines Arcus Biosciences Inc. PDL BioPharma Inc. Pharnext S.A. Polyphor Polyphor Ltd. Sante Ventures Trevena Trevena...
BioCentury | May 30, 2019
Finance

Santé seeks bigger stakes with $250M new fund

...disease play Lumos Pharma Inc. Santé has $525 million under management, Lalande said. Chris Lieu, Staff Writer Sante Ventures...
BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BioCentury | Apr 11, 2016
Financial News

Lumos completes venture financing

...financing Raised: $34 million Investors: Deerfield Management; Clarus Ventures; Roche Venture Fund; New Enterprise Associates; Sante Ventures...
BioCentury | Apr 7, 2016
Financial News

Orphan play Lumos raises $34M

...Clarus Ventures and Roche Venture Fund also participated, as did existing investors New Enterprise Associates, Sante Ventures...
BioCentury | May 4, 2015
Financial News

Mirna completes venture financing

...Cancer Date completed: 2015-04-30 Type: Venture financing Raised: $41.8 million Investors: Baxter Ventures; Eastern Capital; Sante Ventures...
BioCentury | May 1, 2015
Financial News

Mirna raises $41.8M in series D

...series D round led by new investor Baxter Ventures. Other new investors included Eastern Capital; Sante Ventures...
Items per page:
1 - 10 of 24
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS. Libra Therapeutics Inc. emerged from stealth Wednesday...
BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

RA Capital to fund Novavax Novavax Inc. (NASDAQ:NVAX) said Monday it will raise $200 million through a private placement of 4.4 million shares at $45.57, its closing price on Friday, to RA Capital Management. The...
BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

Lumos finds public pat h Rare disease company Lumos Pharma Inc. plans to go public via a reverse merger with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’...
BioCentury | Jun 28, 2019
Company News

Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more

...She was chair of Mintz’s FDA practice. BioCentury Staff Adaptimmune Adaptimmune Ltd. Ambys Medicines Arcus Biosciences Inc. PDL BioPharma Inc. Pharnext S.A. Polyphor Polyphor Ltd. Sante Ventures Trevena Trevena...
BioCentury | May 30, 2019
Finance

Santé seeks bigger stakes with $250M new fund

...disease play Lumos Pharma Inc. Santé has $525 million under management, Lalande said. Chris Lieu, Staff Writer Sante Ventures...
BioCentury | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BioCentury | Apr 11, 2016
Financial News

Lumos completes venture financing

...financing Raised: $34 million Investors: Deerfield Management; Clarus Ventures; Roche Venture Fund; New Enterprise Associates; Sante Ventures...
BioCentury | Apr 7, 2016
Financial News

Orphan play Lumos raises $34M

...Clarus Ventures and Roche Venture Fund also participated, as did existing investors New Enterprise Associates, Sante Ventures...
BioCentury | May 4, 2015
Financial News

Mirna completes venture financing

...Cancer Date completed: 2015-04-30 Type: Venture financing Raised: $41.8 million Investors: Baxter Ventures; Eastern Capital; Sante Ventures...
BioCentury | May 1, 2015
Financial News

Mirna raises $41.8M in series D

...series D round led by new investor Baxter Ventures. Other new investors included Eastern Capital; Sante Ventures...
Items per page:
1 - 10 of 24